Circulating PRCP in STEMI Patients Undergoing Primary PCI

Qilu Hospital of Shandong University4 sites in 1 country275 target enrollmentMay 2016

ConditionsMyocardial Infarction Percutaneous Coronary Intervention PRCP

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Myocardial Infarction
Sponsor: Qilu Hospital of Shandong University
Enrollment: 275
Locations: 4
Primary Endpoint: Circulating PRCP level
Status: Completed
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Purpose: The purpose of this study is to evaluate the impact of acute ST-segment elevation myocardial infarction (STEMI) and primary percutaneous coronary intervention (PCI) on circulating prolylcarboxypeptidase (PRCP) level and activity.

Registry

clinicaltrials.gov

Start Date

May 2016

End Date

July 2016

Last Updated

6 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Qilu Hospital of Shandong University

Responsible Party

Principal Investigator

Pan-Pan Hao

MD, PhD

Qilu Hospital of Shandong University

Eligibility Criteria

Inclusion Criteria

•Admitted for primary PCI for STEMI involving the LAD within 12 hours of onset of symptoms. STEMI will be defined as typical ECG changes (ST segment elevation ≥2mm in 2 or more precordial leads) associated with acute chest pain or an elevation of cardiac enzymes;
•Age ≥18 years;
•Informed consent from subject or next of kin.

Exclusion Criteria

•Nonischaemic Cardiomyopathy;
•Cardiac surgery planed in the 6 months;
•Mechanical complication of STEMI (ventricular septal rupture, free wall rupture, acute severe mitral regurgitation);
•Renal or hepatic failure;
•Malignancy, HIV, or central nervous system disorder;
•Cardiopulmonary resuscitation \>15 min and compromised level of consciousness;
•Cardiogenic shock;
•Current participation in any research study involving investigational drugs or devices;
•No written consensus;
•Previous myocardial infarction.